SAN DIEGO, March 23, 2020 /PRNewswire/ -- Shareholder Rights
Law Firm Johnson Fistel, LLP, is investigating potential claims
against Milestone Pharmaceuticals Inc. (NASDAQ: MIST)
("Milestone or the "Company") for violations of federal
securities laws.
On or about May 9, 2019, Milestone
sold about 5.5 million shares of stock in its initial public stock
offering (the "IPO"), at $15.00 a
share raising approximately $82,500,000 in new capital. However, since
the IPO, Milestone stock has plunged, on March 23, 2020, in after-market trading shares
traded as low as $2.70 on heavy
volume.
Specifically, Johnson Fistel's
investigation seeks to determine whether the Company's filings with
the U.S. Securities and Exchange Commission in connection with its
May 2019 IPO and subsequent investor
communications contained untrue statements of material facts or
omitted to state other facts necessary to make the statements made
therein not misleading concerning the Company's business, and
operations.
If you have information that could assist in this
investigation, or if you are a Milestone shareholder
and are interested in learning more about the investigation, please
contact Jim Baker
(jimb@johnsonfistel.com) at 619-814-4471. If emailing, please
include a phone number.
Additionally, you can [Click here to join this action].
There is no cost or obligation to you.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a
nationally recognized shareholder rights law firm with offices in
California, New York and Georgia. The firm represents individual and
institutional investors in shareholder derivative and securities
class action lawsuits. For more information about the firm and its
attorneys, please visit http://www.johnsonfistel.com. Attorney
advertising. Past results do not guarantee future outcomes.
Contact:
Johnson
Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
[Click here to join this action]
View original
content:http://www.prnewswire.com/news-releases/milestone-mist-alert-johnson-fistel-launches-investigation-into-milestone-pharmaceuticals-inc-investors-suffering-losses-encouraged-to-contact-firm-301028677.html
SOURCE Johnson Fistel, LLP